Close

Ligand Pharma (LGND), Tizona Therapeutics Enter OmniAb Platform License Agreement

February 2, 2016 9:14 AM EST Send to a Friend
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Tizona Therapeutics, Inc., an immunology ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login